[Ipilimumab for patients with metastatic melanoma]
Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A, Rey-Ares L, Caccavo F
Record ID 32014000299
Spanish
Authors' objectives:
To assess the available evidence on the efficacy, safety and issues related to coverage policies for the use of ipilimumab in patients with metastatic melanoma.
Authors' recommendations:
The ipilimumab use for the treatment of metastatic melanoma, both as first and second line therapy should be assessed considering that, currently, there is no standard treatment for this disease, although the use of dacarbazine is widespread. Even though the evidence found comes from RCTs, none of the studies directly compared ipilimumab versus dacarbazine or placebo. Ipilimumab as monotherapy proved to be better than the gp100 vaccine and in combination with dacarbazine, proved to be better than dacarbazine as monotherapy. Although its cost-effectiveness has not been evaluated, it should be considered that the cost of the ipilimumab therapy is approximately 40 times higher than that of dacarbazine therapy.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
https://www.iecs.org.ar/home-ets/?cod_publicacion=1386&origen_publicacion=publicaciones
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Melanoma
- Ipilimumab
- Antibodies, Monoclonal
- Antineoplastic Agents
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.